Modulim
Modulim is dedicated to preventing the complications of chronic wounds due to diabetes, peripheral arterial disease, and burns. Mapping tissue health at the point-of-care is key to preventing non-healing chronic wounds. This is made possible only by Modulim's handheld microvascular imaging solution, powered by Spatial Frequency Domain Imaging (SFDI), that empowers healthcare teams with proprietary data and proactive, personalized AI insights.
Industries
N/A
Nr. of Employees
small (1-50)
Modulim
2755 Bristol Street. Suite 285 Costa Mesa, CA 92626
Modulim is currently seeking investment
Modulim is seeking a series-a investment in the range of 5m-20m
Awards
Burn Digital Assessment
Advanced Handheld Spectral and Spatial-Frequency Domain Imaging Camera for Burn Assessment and Total Body Surface Area Mapping
Funding (ceiling)
$5,684,463.26
Award Year
2023
Products
Non-contact optical imaging system for microvascular assessment
A point-of-care, non-contact imaging system that uses structured-light multispectral imaging to quantify tissue oxygenation and hemoglobin distribution and produce 2D biomarker maps; reported as cleared by relevant regulatory bodies.
Non-contact optical imaging system for microvascular assessment
A point-of-care, non-contact imaging system that uses structured-light multispectral imaging to quantify tissue oxygenation and hemoglobin distribution and produce 2D biomarker maps; reported as cleared by relevant regulatory bodies.
Expertise Areas
- Microvascular optical imaging
- Point-of-care diagnostics for tissue perfusion
- Clinical validation and biomarker research
- Medical device development and regulatory compliance
Key Technologies
- Spatial frequency domain imaging (SFDI)
- Structured-light multispectral imaging (visible and near-infrared)
- Layer-specific hemoglobin and oxygenation mapping
- Cloud-based HIPAA-compliant analytics
Key People
News & Updates
Modulim received a three-year renewal of their ISO:13485 certification after a comprehensive review of the company’s quality system.
Modulim announced the grant of United States Patent US11751769B2 for systems and methods to assess diabetic circulatory complications.
A new clinical case study was published assessing the impact of revascularization on microvascular oxygenation and perfusion using SFDI.
Patent granted for a system and method to assess diabetic circulatory complications.
Modulim received a three-year renewal of their ISO:13485 certification after a comprehensive review of the company’s quality system.
Modulim announced the grant of United States Patent US11751769B2 for systems and methods to assess diabetic circulatory complications.
A new clinical case study was published assessing the impact of revascularization on microvascular oxygenation and perfusion using SFDI.
Patent granted for a system and method to assess diabetic circulatory complications.